• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azolidines Imidazolidinones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azolidines Imidazolidines Imidazolidinones

Recent Advances in the Study of 5,5-Diphenylhydantoin Calcium Salt (CAS: 17199-74-5)

5,5-Diphenylhydantoin calcium salt (CAS: 17199-74-5) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. This compound, a calcium salt derivative of phenytoin, has been widely studied for its pharmacological properties, particularly in the context of anticonvulsant and antiarrhythmic applications. Recent studies have further explored its mechanisms of action, potential therapeutic uses, and novel synthetic pathways, making it a focal point in contemporary research.

One of the key areas of recent investigation involves the compound's interaction with voltage-gated sodium channels. Research has demonstrated that 5,5-Diphenylhydantoin calcium salt exhibits a stabilizing effect on neuronal membranes by modulating these channels, thereby reducing excessive electrical activity in the brain. This mechanism underpins its efficacy in treating epilepsy and other seizure disorders. Advanced electrophysiological studies have provided deeper insights into the kinetics of channel blockade, offering potential for improved therapeutic strategies.

In addition to its neurological applications, recent studies have explored the compound's potential in cardiovascular medicine. Preliminary findings suggest that 5,5-Diphenylhydantoin calcium salt may possess antiarrhythmic properties, attributed to its ability to regulate calcium ion flux in cardiac tissues. These findings open new avenues for research into its use in managing cardiac arrhythmias, although further clinical validation is required.

The synthesis and formulation of 5,5-Diphenylhydantoin calcium salt have also seen advancements. Novel synthetic routes have been developed to enhance yield and purity, addressing previous challenges in large-scale production. Furthermore, researchers have investigated its compatibility with various drug delivery systems, including nanoparticles and liposomes, to improve bioavailability and targeted delivery.

Despite these promising developments, challenges remain. The compound's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME) properties, requires further elucidation to optimize dosing regimens. Additionally, potential side effects and drug interactions necessitate comprehensive safety assessments in both preclinical and clinical settings.

In conclusion, 5,5-Diphenylhydantoin calcium salt continues to be a compound of great interest in chemical biology and pharmaceutical research. Its multifaceted pharmacological properties and recent advancements in understanding its mechanisms and applications highlight its potential for future therapeutic innovations. Ongoing research is expected to further refine its use and explore new indications, solidifying its role in modern medicine.

• 6859-11-6(2,4-Imidazolidinedione, 1-methyl-5,5-diphenyl-)
• 57-41-0(Phenytoin)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)